Genetic analysis of chemoresistance in primary murine lymphomas
- 1 September 2000
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 6 (9), 1029-1035
- https://doi.org/10.1038/79542
Abstract
Understanding the basis of chemoresistance is a principal goal of molecular oncology. We have exploited a murine lymphoma model and retroviral gene transfer to rapidly generate a series of spontaneous tumors differing only in a gene of interest, and subsequently studied the impact of the test gene on the treatment sensitivity of tumors at their natural site. We demonstrate that the Bcl-2 oncoprotein produces multi-drug resistance when assessed in primary lymphomas in vivo. In contrast, this effect was dramatically reduced when the primary lymphomas were subjected to long-term culture, and completely missed in the standard clonogenic survival assay. This model highlights the importance of physiological test systems to address the complexity of clinical drug resistance and provides a novel strategy to evaluate compounds targeting specific genetic lesions.Keywords
This publication has 26 references indexed in Scilit:
- Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumorsOncogene, 2000
- Overexpression of Bcl-xL Promotes Chemotherapy Resistance of Mammary Tumors in a Syngeneic Mouse ModelThe American Journal of Pathology, 1999
- Expression of P53 Predicts Treatment Failure in Aggressive Non-Hodgkin's LymphomasLeukemia & Lymphoma, 1998
- Mutations of the p53 Gene as a Prognostic Factor in Aggressive B-Cell LymphomaNew England Journal of Medicine, 1997
- bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cellsInternational Journal of Cancer, 1997
- Apoptotic cell death induced by c-myc is inhibited by bcl-2Nature, 1992
- Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2Nature, 1990
- Stimulation of B-cell progenitors by cloned murine interleukin-7Nature, 1988
- The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells.The Journal of Experimental Medicine, 1988
- The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic miceNature, 1985